Recent News

• 09.05.2025 - H.C. Wainwright 27th Annual Global Investment Conference
• 09.02.2025 - Lisata Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
• 08.07.2025 - Lisata Therapeutics 2nd Quarter 2025 Financial Results and Business Update Conference Call
• 08.07.2025 - Lisata Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
• 07.31.2025 - Lisata Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Business Update on Thursday, August 7, 2025
• 07.17.2025 - Lisata Therapeutics and WARPNINE Announce iLSTA Trial Enrollment Completion and Provide Preliminary Data Update
• 07.15.2025 - Lisata Therapeutics Expands Intellectual Property Portfolio with New Composition of Matter Patent for Certepetide
• 06.26.2025 - Positive Preliminary Cohort B Results from the AGITG-led ASCEND Trial to be Presented at ESMO GI Evaluating Lisata’s Certepetide in Combination with Standard-of-Care Chemotherapy in Metastatic Pancreatic Cancer
• 06.17.2025 - 2025 BIO International Convention
• 06.17.2025 - Lisata Therapeutics and GATC Health Expand Relationship to Advance AI-Driven Drug Discovery and Development

Recent Filings

• 08.07.2025 - EX-99.1 EX-99.1
• 08.07.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.07.2025 - 8-K Current report
• 07.15.2025 - EX-99.1 EX-99.1
• 07.15.2025 - 8-K Current report
• 06.26.2025 - 8-K Current report
• 06.26.2025 - EX-99.1 EX-99.1
• 06.17.2025 - 8-K Current report
• 06.17.2025 - EX-99.1 EX-99.1
• 06.13.2025 - 8-K Current report